New drug therapies in peripheral T-cell lymphoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 3, 2011, Pages 457-472

  Howman, Rebecca A ^a   Prince, H Miles ^b,c  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

alemtuzumab; angioimmunoblastic lymphoma; denileukin diftitox; gemcitabine; histone deacetylase inhibitors; novel agents; peripheral T cell lymphoma; pralatrexate; romidepsin; targeted cancer therapies; zanolimumab

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; BELINOSTAT; BORTEZOMIB; CLOFARABINE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FOLIC ACID ANTAGONIST; FORODESINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; NELARABINE; OBLIMERSEN; PANOBINOSTAT; PRALATREXATE; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE; ROMIDEPSIN; SIPLIZUMAB; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; ZANOLIMUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STAGING; CAPILLARY LEAK SYNDROME; CHRONIC LYMPHATIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART DEATH; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HERPES SIMPLEX; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; INFECTION COMPLICATION; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL EDEMA; PERIPHERAL T CELL LYMPHOMA; PLEURA EFFUSION; PNEUMONIA; PROLYMPHOCYTIC LEUKEMIA; PRURITUS; QT PROLONGATION; RESPIRATORY FAILURE; REVIEW; SEPSIS; SIDE EFFECT; STOMATITIS; T CELL LEUKEMIA; T CELL LYMPHOMA; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY CAST; VIREMIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FOLIC ACID ANTAGONISTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, T-CELL;

EID: 79952972082     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.4     Document Type: Review

References (157)

1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann. Oncol. 9(7), 717-720 (1998) (Pubitemid 28394156)
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26(25), 4124-4130 (2008)
3. Rodriguez J, Gutierrez A, Martinez-Delgado B, Perez-Manga G. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit. Rev. Oncol. Hematol. 71(3), 181-198 (2009)
4. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues (4th Edition). IARC, Lyon, France (2008)
5. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann. Oncol. 15(10), 1467-1475 (2004) (Pubitemid 39409735)
6. Armitage J, Vose J, Weisenburger D. Towards understanding the peripheral T cell lymphomas. Ann. Oncol. 15, 1447-1449 (2004) (Pubitemid 39409731)
7. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93(11), 3913-3921 (1999) (Pubitemid 29249840)
8. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d?Etudes des Lymphomes de l?Adulte (GELA). Blood 92(1), 76-82 (1998) (Pubitemid 28303178)
9. Fisher RI, Gaynor ER, Dahlberg S, et al. A Phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediateor high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann. Oncol. 5(Suppl. 2), 91-95 (1994) (Pubitemid 24061327)
10. Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the MD Anderson Cancer Center experience. Cancer 103(10), 2091-2098 (2005) (Pubitemid 40605117)
11. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83(9), 2451-2458 (2005)
12. Rassidakis GZ, Jones D, Lai R, et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J. Pathol. 200(2), 240-248 (2003) (Pubitemid 36748033)
13. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 333(23), 1540-1545 (1995)
14. d?Amore F, Relander T, Lauritzsen GF. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remission in a large fraction of patients with previously untreated peripheral T-cell lymphoma (PTCLs) -overall and subtype-specific results of a Phase II study from the Nordic Lymphoma Group. Presented at: Annual Meeting of the European Haematology Association. Berlin, Germany, 4-6 June 2009
15. Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol. 27(1), 106-113 (2009)
16. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J. Clin. Oncol. 22(11), 2172-2176 (2004) (Pubitemid 41095152)
17. Horwitz SM. Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology Am. Soc. Hematol. Educ. Program 289-296 (2008)
18. No authors listed. StatBite: FDA oncology drug product approvals in 2009. J. Natl Cancer Inst. 102(4), 219 (2010)
19. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother. Pharmacol. 42(4), 313-318 (1998) (Pubitemid 28393849)
20. Wang ES, O"Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk. Lymphoma 44(6), 1027-1035 (2003) (Pubitemid 36417003)
21. O?Connor OA. Developing new drugs for the treatment of lymphoma. Eur. J. Haematol. Suppl. 66, 150-158 (2005)
22. O?Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br. J. Haematol. 139(3), 425-428 (2007) (Pubitemid 47512170)
23. O?Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a highaffinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J. Clin. Oncol. 27(26), 4357-4364 (2009)
24. Mould DR, Sweeney K, Duffull SB, et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin. Pharmacol. Ther. 86(2), 190-196 (2009)
25. Pro B, Coiffier B, Horwitz SM, et al. Correlation between baseline methylmalonic acid status and mucositis severity in the PROPEL study: implications for vitamin prophylaxis. ASH (Annual Meeting Abstracts) 114(22), 1681 (2009)
26. O?Connor O, Pro B, Pinter-Brown L, et al. PROPEL: results of the pivotal, multicenter, Phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). J. Clin. Oncol. (Meeting Abstracts). 27(15S), 8561 (2009)
27. Pinter-Brown L, Horwitz SM, Pro B, et al. Safety and management of pralatrexate treatment in relapsed or refractory peripheral T-cell lymphoma (PTCL). ASH (Annual Meeting Abstracts) 114(22), 1675 (2009)
28. Savage KJ, Shustov AR, Goy A, et al. Pralatrexate induces responses in patients with highly refractory peripheral T-cell lymphoma (PTCL). ASH (Annual Meeting Abstracts) 114(22), 1678 (2009)
29. Marchi E, Paoluzzi L, Scotto L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin. Cancer Res. 16(14), 3648-3658 (2010)
30. Horwitz SM, Vose JM, Advani R, et al. Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: Phase 1 results. ASH (Annual Meeting Abstracts) 114(22), 1674 (2009)
31. Horwitz SM, Vose JM, Advani R, et al. A Phase 1/2A open-label study of pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies. ASH (Annual Meeting Abstracts) 112(11), 1570 (2008)
32. Jones LK, Saha V. Chromatin modification, leukaemia and implications for therapy. Br. J. Haematol. 118(3), 714-727 (2002) (Pubitemid 35007375)
33. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1(3), 194-202 (2001) (Pubitemid 33741894)
34. Johnstone RW, Licht JD Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4(1), 13-18 (2003) (Pubitemid 36904157)
35. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006) (Pubitemid 44348499)
36. Richon V. Mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br. J. Cancer 95, S2-S6 (2006) (Pubitemid 44950782)
37. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 23(17), 3971-3993 (2005) (Pubitemid 46218700)
38. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res. 15(12), 3947-3957 (2009)
39. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 15(12), 3958-3969 (2009)
40. Rasheed W, Bishton M, Johnstone RW, Prince HM. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev. Anticancer Ther. 8(3), 413-432 (2008) (Pubitemid 351836289)
41. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin. Cancer Res. 15(12), 3918-3926 (2009)
42. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 12(13), 3997-4003 (2006) (Pubitemid 44078086)
43. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin. Cancer Res. 12(12), 3762-3773 (2006) (Pubitemid 44000258)
44. Zhang QL, Wang L, Zhang YW, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 23(8), 1507-1514 (2009)
45. Heider U, Rademacher J, Lamottke B, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur. J. Haematol. 82(6), 440-449 (2009)
46. Kelly WK, O?Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23(17), 3923-3931 (2005) (Pubitemid 46218695)
47. Kelly WK, Richon VM, O?Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9(10 Pt 1), 3578-3588 (2003) (Pubitemid 37169221)
48. O?Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24(1), 166-173 (2006) (Pubitemid 46630509)
49. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247-1252 (2007) (Pubitemid 350106355)
50. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1), 31-39 (2007) (Pubitemid 46053039)
51. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109-3115 (2007) (Pubitemid 47218059)
52. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res. 13(8), 2318-2322 (2007) (Pubitemid 46698579)
53. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62(17), 4916-4921 (2002) (Pubitemid 34984414)
54. Woo S, Gardner ER, Chen X, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin. Cancer Res. 15(4), 1496-1503 (2009)
55. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98(9), 2865-2868 (2001)
56. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009)
57. Bates S, Piekarz R, Wright J, et al. Final clinical results of a Phase 2 NCI multicenter study of romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included). ASH (Annual Meeting Abstracts) 112(11), 1568 (2008)
58. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28(29), 4485-4491 (2010)
59. Piekarz R, Wright J, Frye R, et al. Final results of a Phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). ASH (Annual Meeting Abstracts) 114(22), 1657 (2009)
60. Piekarz RL, Frye R, Prince HM. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood DOI: 10.1182/blood-2010-10-312603 (2011) (Epub ahead of print)
61. Coiffier B, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, Phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. ASH (Annual Meeting Abstracts) 116(21), 114 (2010)
62. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res. 14(14), 4500-4510 (2008)
63. Duvic M, Becker JC, Dalle S, et al. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL). ASH (Annual Meeting Abstracts) 112(11), 1005 (2008)
64. Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. ASH (Annual Meeting Abstracts) 112(11), 958 (2008)
65. Zain JM, O?Connor O, Zinzani PL, Norman A, de Nully Brown P. Multicenter, open-label trial of PXD 101 in patients with relapsed/refractory peripheral T-cell lymphoma. J. Clin. Oncol. (Meeting Abstracts). 28(15 Suppl.), e18565 (2010)
66. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr. Med. Chem. 13(26), 3165-3189 (2006) (Pubitemid 44680862)
67. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br. J. Haematol. 113(1), 185-187 (2001) (Pubitemid 32423320)
68. Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann. Oncol. 21(4), 860-863 (2010)
69. Kim JG, Sohn SK, Chae YS, et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother. Pharmacol. 58(1), 35-39 (2006)
70. Emmanouilides C, Colovos C, Pinter-Brown L, et al. Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin. lymp. 5(1), 45-49 (2004) (Pubitemid 39136442)
71. Arkenau HT, Chong G, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2), 271-272 (2007) (Pubitemid 46852437)
72. Spencer A, Reed K, Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Int. Med. J. 37(11), 760-766 (2007) (Pubitemid 47512336)
73. Marchi E, Paoluzzi L, Venkatraman SE, O?Connor OA. Pralatrexate (PDX) compliments the activity of the proteasome inhibitor bortezomib (B) in in vitro models of lymphoid T-cell malignancies. Blood ASH (Annual Meeting Abstracts) 112 (2008) (Abstract 3619)
74. Kicska GA, Long L, Horig H, et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc. Natl Acad. Sci. USA 98(8), 4593-4598 (2001) (Pubitemid 32295021)
75. Furman RR, Gore L, Ravandi F, Hoelzer D. Forodesine IV (Bcx-1777) is clinically active in relapsed/refractory T-cell leukemia: results of a Phase II study (interim report). ASH (Annual Meeting Abstracts) 108(11), 1851 (2006)
76. Duvic M, Forero-Torres A, Foss F, Olsen E, Kim Y. Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a Phase I/II study. ASH (Annual Meeting Abstracts) 110(11), 122 (2007)
77. Duvic M, Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y. Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. J. Clin. Oncol. (Meeting Abstracts) 27(15S), 8552 (2009)
78. Robak T, Korycka A, Lech-Maranda E, Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 14(3), 1183-1226 (2009)
79. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J. Clin. Oncol. 23(15), 3376-3382 (2005)
80. Czuczman MS, Porcu P, Johnson J, et al. Results of a Phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk. Lymphoma 48(1), 97-103 (2007) (Pubitemid 46978628)
81. Mulford DA, Pohlman BL, Hamlin PA, Young F, Pamer E, Horwitz SM. A Phase I/II trial of clofarabine in patients with relapsed T-cell or NK-cell lymphomas. J. Clin. Oncol. (Meeting Abstracts) 28(15 Suppl.), 8046 (2010)
82. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Blood 116(18), 3418-3425 (2010)
83. Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J. Clin. Pathol. 47(4), 313-317 (1994) (Pubitemid 24171697)
84. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. 22(2), 185-191 (1998) (Pubitemid 28185349)
85. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98(6), 1721-1726 (2001)
86. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101(11), 4267-4272 (2003) (Pubitemid 36857787)
87. Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur. J. Haematol. 71(4), 250-256 (2003) (Pubitemid 37174695)
88. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103(8), 2920-2924 (2004) (Pubitemid 38451660)
89. Kim SJ, Kim K, Kim BS, et al. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a Phase II prospective study. Ann. Oncol. 20(2), 390-392 (2009)
90. Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M. Preliminary observations of a Phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90(5), 702-703 (2005) (Pubitemid 40780898)
91. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7), 2316-2323 (2007) (Pubitemid 47523150)
92. Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a Phase II study. Cancer Chemother. Pharmacol. 60(1), 129-134 (2007) (Pubitemid 46643727)
93. Geissinger E, Bonzheim I, Roth S, Rosenwald A, Muller-Hermelink HK, Rudiger T. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk. Lymphoma 50(6), 1010-1016 (2009)
94. Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br. J. Haematol. 145(2), 173-179 (2009)
95. Amengual JE, Raphael BG. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma. Leuk. Lymphoma 51(7), 1347-1350 (2010)
96. Halene S, Zieske A, Berliner N. Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat. Clin. Pract. Oncol. 3(3), 165-168; quiz 169 (2006)
97. Villadsen LS, Skov L, Dam TN, et al. In situ depletion of CD4+ T cells in human skin by zanolimumab. Arch. Dermatol. Res. 298(9), 449-455 (2007) (Pubitemid 46144206)
98. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4), two Phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109(11), 4655-4662 (2007) (Pubitemid 46827755)
99. Mestel DS, Beyer M, Mobs M, Steinhoff M, Sterry W, Assaf C. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sezary syndrome. Expert Opin. Biol. Ther. 8(12), 1929-1939 (2008)
100. d?Amore F, Radford J, Relander T, et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory noncutaneous peripheral T cell lymphoma. Br. J. Haematol. 150(5), 565-573 (2010)
101. O?Mahony D, Morris JC, Moses L, et al. Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. ASH (Annual Meeting Abstracts) 106(11), 3353 (2005)
102. O?Mahony D, Morris JC, Stetler-Stevenson M, et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin. Cancer Res. 15(7), 2514-2522 (2009)
103. Waters CA, Schimke PA, Snider CE, et al. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol. 20(4), 785-791 (1990) (Pubitemid 20167033)
104. Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 28(11), 1870-1877 (2010)
105. ®) in the treatment of cutaneous T-cell lymphoma (CTCL) according to CD25 status. Blood (ASH Annual Meeting Abstracts) 108 (2006) (Abstract 2712)
106. Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br. J. Haematol. 136(3), 439-447 (2007) (Pubitemid 46046302)
107. Foss FM, Sjak-Shie NN, Goy A, Advani R, Jacobsen ED. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. ASCO Meeting Abstracts 28(15 Suppl.), 8045 (2010)
108. Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood 104(3), 802-809 (2004) (Pubitemid 38970577)
109. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(27), 4293-4297 (2007) (Pubitemid 47548570)
110. Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann. Oncol. 19(12), 2079-2083 (2008)
111. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105(8), 3058-3065 (2005)
112. Delmer A, Fitoussi O, Gaulard P, et al. A Phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial. ASCO Meeting Abstracts. 27(15S), 8554 (2009)
113. Dueck G, Chua N, Prasad A, et al. Interim report of a Phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116(19), 4541-4548 (2010)
114. Hess G, Smith SM, Berkenblit A, Coiffier B. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin. Oncol. 36(Suppl. 3), S37-S45 (2009)
115. Ansell SM, Tang H, Kurtin P, et al. A Phase II Study of temsirolimus (CCI-779) in combination with rituximab in patients with relapsed or refractory mantle cell lymphoma. ASH (Annual Meeting Abstracts) 114(22), 1665 (2009)
116. Johnston PB, Ansell SM, Colgan JP, et al. mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001). ASH (Annual Meeting Abstracts) 110(11), 2555 (2007)
117. Guenther A, Baumann P, Burger R, Klapper W, Schmidmaier R, Gramatzki M. Phase I/II study with single agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma. ASH (Annual Meeting Abstracts) 114(22), 3850 (2009)
118. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 12(17), 5165-5173 (2006) (Pubitemid 44453345)
119. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 15(4), 1126-1132 (2009)
120. Jung JT, Kim DH, Kwak EK, et al. Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. Ann. Hematol. 85(9), 575-581 (2006) (Pubitemid 44283077)
121. Wilson W, O?Connor OO, Roberts AW, et al. ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). J. Clin. Oncol. (Meeting Abstracts) 27(15S), 8574 (2009)
122. Wilson WH, O?Connor OA, Czuczman MS, et al. Phase 1/2a Study of ABT-263 in relapsed or refractory lymphoid malignancies. ASH (Annual Meeting Abstracts) 114(22), 1711 (2009)
123. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 80(7), 1804-1812 (1992)
124. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology 50(4), 498-508 (2007) (Pubitemid 46328187)
125. Dunleavy K, Wilson WH. Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy. Leuk. Lymphoma 48(3), 449-451 (2007) (Pubitemid 46487748)
126. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br. J. Haematol. 148(5), 673-689 (2010)
127. Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH. Angioimmunoblastic T-cell lymphoma. Crit. Rev. Oncol. Hematol. 68(3), 264-271 (2008)
128. Alizadeh AA, Advani RH. Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin. Adv. Hematol. Oncol. 6(12), 899-909 (2008)
129. Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d?Etude des Lymphomes de l?Adulte (GELA) trials. Blood 111(9), 4463-4470 (2008)
130. Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk. Lymphoma 48(3), 521-525 (2007) (Pubitemid 46487759)
131. Joly B, Plonquet A, Grare M, et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: results of the Phase II RAIL trial -a prospective study of the Groupe d?Etude des Lymphomes de l?Adulte (GELA). J. Clin. Oncol. (Meeting Abstracts) 28(15 Suppl.) (2010)
132. Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 19(11), 1993-1995 (2005) (Pubitemid 41554011)
133. Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann. Oncol. 19(2), 396-397 (2008) (Pubitemid 351201728)
134. Advani RH, Hong F, Ganjoo KN, et al. Cardiac toxicity associated with the anti-VEGF monoclonal antibody bevacizumab (Avastin) in combination with CHOP (A-CHOP) chemotherapy for peripheral T cell lymphoma (PTCL): the ECOG 2404 trial. ASH (Annual Meeting Abstracts) 114(22), 1671 (2009)
135. Gottardi M, Danesin C, Canal F, et al. Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation. Leuk. Lymphoma 49(9), 1836-1838 (2008)
136. Ramasamy K, Lim Z, Pagliuca A. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica 91(8 Suppl.), ECR44 (2006)
137. Dogan A, Ngu LS, Ng SH, Cervi PL. Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia 19(5), 873-875 (2005) (Pubitemid 40663113)
138. Strupp C, Aivado M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk. Lymphoma 43(1), 133-137 (2002) (Pubitemid 34223981)
139. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96(12), 3681-3695 (2000)
140. Sandlund JT, Pui CH, Roberts WM, et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 84(8), 2467-2471 (1994)
141. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev. Anticancer Ther. 9(3), 331-356 (2009)
142. Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 94(10), 3509-3515 (1999) (Pubitemid 29536146)
143. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br. J. Haematol. 146(2), 171-179 (2009)
144. Blum KA, Johnson JL, Jung SH, Cheson BD, Bartlett NL. Serious pulmonary toxicity with SGN-30 and gemcitabine, vinorelbine, and liposomal doxorubicin in patients with relapsed/refractory Hodgkin lymphoma (HL): cancer and leukemia group B (CALGB) 50502. Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 232)
145. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J. Clin. Oncol. 25(19), 2764-2769 (2007) (Pubitemid 47123185)
146. Younes A, Zalevsky J, Blum KA, et al. Evaluation of the pharmacokinetics, immunogenicity, and safety of XmAb®2513 in the ongoing study XmAb2513-01: a Phase 1 study of every other week XmAb2513 to evaluate the safety, tolerability, and pharmacokinetics in patients with Hodgkin lymphoma or anaplastic large cell lymphoma. Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 5012)
147. Hamblett KJ, Barton J, Cerveny CG, et al. SGN-35, an Anti-CD30 Antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ Malignancies. Blood (ASH Annual Meeting Abstracts) 106 (2005) (Abstract 610)
148. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812-1821 (2010)
149. Shustov AR, Advani R, Brice P, et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. ASH (Annual Meeting Abstracts) 116(21), 961 (2010)
150. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010)
151. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of cases from the International Peripheral T-cell Lymphoma Project. Blood 113(17), 3931-3937 (2009)
152. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J. Clin. Oncol. 24(1), 181-189 (2006) (Pubitemid 46630511)
153. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann. Oncol. 15(4), 618-625 (2004)
154. Yong W, Zheng W, Zhu J, et al. l-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann. Hematol. 88(7), 647-652 (2009)
155. Jaccard A, Gachard N, Marin B, et al. Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a Phase II study. Blood 117(6), 1834-1839 (2010)
156. ClinicalTrials.gov trials NCT00217425 http://clinicaltrials.gov/ct2/show/ NCT00217425
157. ClinicalTrials.gov trials NCT00958854 http://clinicaltrials.gov/ct2/show/ NCT00958854